# PATENT COOPERATION TREATY

# **PCT**

# INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	FOR FURTHER		COO Form DCT/ICA MOO
X62816PC	ACTION	as well	see Form PCT/ISA/220 las, where applicable, item 5 below.
International application No.	International filing date (day/monti	vyear)	(Earliest) Priority Date (day/month/year)
PCT/EP2004/006265	09/06/2004		10/06/2003
Applicant			L
XANTOS BIOMEDICINE AG	·		
This International Search Report has been according to Article 18. A copy is being tra	n prepared by this International Sea ansmitted to the International Bureau	ching Auth	nority and is transmitted to the applicant
This International Search Report consists	of a total of she	ets.	·.
X It is also accompanied by	a copy of each prior art document o	ted in this	report.
Basis of the report			
<ul> <li>a. With regard to the language, the language in which it was filed, unli</li> </ul>	international search was carried out ess otherwise indicated under this it	on the bas em.	sis of the international application in the
The international this Authority (Rul	search was carried out on the basis	of a transla	ation of the international application furnished to
	` ''	disclosed	in the international application, see Box No. I.
Z     Certain claims were four	nd unsearchable (See Box II).		
3. Unity of invention is lack	king (see Box III).		
4. With regard to the title,	,		
the text is approved as sul	bmitted by the applicant		
	hed by this Authority to read as follo	ws.	
ANGIOGENIC FACTOR AND			
	• • •		•
5. With regard to the abstract,			
the text is approved as sul	•		
may, within one month from	m the date of mailing of this internat	onal searc	y as it appears in Box No. IV. The applicant the report, submit comments to this Authority.
6. With regards to the drawings,			·
a. the figure of the drawings to be po	ublished with the abstract is Figure !	No	
as suggested by the			•
as selected by this	s Authority, because the applicant fa	led to sug	gest a figure.
<del>p The said</del>	s Authority, because this figure bette	r character	rizes the invention.
b. X none of the figures is to be	published with the abstract.		

# BEST AVAILABLE COPY

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP2004/006265

Вох	No. I	N	ucleotide and/o	or amino a	acid seque	ence(s) (Con	tinuation of item	1.b of the f	irst sheet)		
1.	With	regard	to any nucleotide e international se	and/or ami arch was ca	no acid sequarried out on	uence disclose the basis of:	d in the internationa	al application a	ınd necessar	y to the claim	ned
	a.	type of	f material a sequence listi table(s) related	_	ence listing						
	b.	format X X	of material in written format in computer rea								
2.	с.	X X In ac or fu	furnished subsedidition, in the case	th the interr quently to the e that more	national appli his Authority than one ve	for the purpos	f a sequence listing	additional coni	ae ie idantiaa	to has been f il to that in th	filled e
3.	Addit	appi	omments:	aoes not go	beyond the	application as	filed, as appropriat	e, were furnisl	ned. :.		
							*				
		٠.							. <del>2</del>		

#### International application No.

#### INTERNATIONAL SEARCH REPORT

Text of the abstract (Continuation of item 5 of the first sheet)

Box No. IV

PCT/EP2004/006265

The present invention relates to inhibitors of a novel angiogenic factor, SEP,

and soluble derivatives thereof and to their use in pharmaceutical compositions.

### INTERNATIONAL SEARCH REPORT

International Application No PCT/EP2004/006265

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 C07K14/47 A61K38/17

According to International Patent Classification (IPC) or to both national classification and IPC

#### **B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols) I PC  $\,\,7\,\,$  C  $\,07\,K$ 

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE, Sequence Search

ENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
WO 02/053737 A (NAGANO YUKIKO; HONDA GOICHI (JP); MATSUDA AKIO (JP); MURAMATSU SHUJI) 11 July 2002 (2002-07-11) SEQ ID NO's 169 & 170	1-9, 11-15, 17-19
same passages	1-19
WO 99/06552 A (GENSET SA; LACROIX BRUNO (FR); DUCLERT AYMERIC (FR); DUMAS MILNE EDWA) 11 February 1999 (1999-02-11) SEQ ID NO: 153 pages 1-12 examples 43.62.63	1-9, 11-15, 17-19
same passages	1-19
	Citation of document, with indication, where appropriate, of the relevant passages  WO 02/053737 A (NAGANO YUKIKO; HONDA GOICHI (JP); MATSUDA AKIO (JP); MURAMATSU SHUJI) 11 July 2002 (2002-07-11) SEQ ID NO's 169 & 170 pages 1-58 same passages  WO 99/06552 A (GENSET SA; LACROIX BRUNO (FR); DUCLERT AYMERIC (FR); DUMAS MILNE EDWA) 11 February 1999 (1999-02-11) SEQ ID NO: 153 pages 1-12 examples 43,62,63

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
Special categories of cited documents:  'A' document defining the general state of the art which is not considered to be of particular relevance  'E' earlier document but published on or after the international filling date  'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)  'O' document referring to an oral disclosure, use, exhibition or other means  'P' document published prior to the international filing date but later than the priority date claimed	<ul> <li>'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>'&amp;' document member of the same patent family</li> </ul>
Date of the actual completion of the international search  29 October 2004	Date of mailing of the international search report 25/11/2004
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL - 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  Fax: (+31-70) 340-3016	Authorized officer Steffen, P

NAME OF THE PARTY	PCT/EP2004/006265
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
DATABASE EMBL EBI; 4 January 2002 (2002-01-04), STRAUSBERG RL ET AL.: "Mus musculus RIKEN cDNA D430028G21 gene, mRNA (cDNA clone MGC:25836 IMAGE:4190175), complete cds." XP002297872 Database accession no. BC020006	1-19
DATABASE EMBL EBI; 30 January 2003 (2003-01-30), STRAUSBERG RL ET AL.: "Homo sapiens KIAA1271 protein, mRNA (cDNA clone MGC:50830 IMAGE:5751684), complete cds." XF002297873 Latatar accession no. BC0044952 at trais sequences	1-19
The state of the s	1-19
IHOMPSON J D: "Applications of antisense and siRNAs during preclinical drug development" DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD. GB. vol. 7. no. 17, 1 September 2002 (2002-09-01), pages 912-917, XP002236964 ISSN: 1359-6446 the whole document	6
WO 03/048202 A (MATSUDA AKIO; MURAMATSU SHUJI (JF): ASAHI CHEMICAL IND (JP)) 12 June 2003 (2003-06-12) SEQ ID NO's 43-46 pages 1-64	1-9, 11-15, 17-19
	DATABASE EMBL EBI; 4 January 2002 (2002-01-04), STRAUSBERG RL ET AL.: "Mus musculus RIKEN cDNA D430028G21 gene, mRNA (cDNA clone MGC:25836 IMAGE:4190175), complete cds." XP002297872 Database accession no. BC020006 abstract; sequences  DATABASE EMBL EBI; 30 January 2003 (2003-01-30), STRAUSBERG RL ET AL.: "Homo sapiens KIAA1271 protein, mRNA (cDNA clone MGC:50830 IMAGE:5751684), complete cds." XF002291873 (atatain accession no. BC0044952 d: trais sequences  MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease that activate NF-kappaB and MACHIEL A: 10 ET AL: "Large-scale decrease decr

# INTERNATIONAL SEARCH REPORT

	İ
ı	
1	
-	
j	$\mathbf{u}$
- [	П
(	$\mathbf{C}$
4	1
	•
]	Δ
٩	٧
]	Š
3	li
Ų	
4	2
Q	ַ
П	_
П	П
q	)
1	)
7	5
١.	2
٦	

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:	
Although claims 12-18 are directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.	
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)	_
This International Searching Authority found multiple inventions in this international application, as follows:	
	9
1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	•
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
	į
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	j
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest  The additional search fees were accompanied by the applicant's protest.	
No protest accompanied the payment of additional search fees.	

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP2004/006265

Patent document cited in search report		Publication date	Patent family member(s)			Publication date	
WO 02053737	Α	11-07-2002	EP WO US US	1354950 02053737 2003170719 2004081986	A1 A1	22-10-2003 11-07-2002 11-09-2003 29-04-2004	
WO 9906552	A	11-02-1999	US AU CA EP WO JP	6222029 8555598 2296667 1000150 9906552 2001512015	A A1 A2 A2	24-04-2001 22-02-1999 11-02-1999 17-05-2000 11-02-1999 21-08-2001	
WO 03048202	Α	12-06-2003	WO	03048202	A2	12-06-2003	